Journal rankings · indicator year 2024
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Domain ranking · 2024
Health Sciences journal rankings 2024
5,549 ranked journals · Domain
Health Sciences has 5,549 ranked journals in 2024. The median journal has an OJR of 0.68, below the world average of 1.00, unchanged on 2023; Q1 starts at OJR 1.10. The top three are CA A Cancer Journal for Clinicians, MMWR Surveillance Summaries, and Nature Reviews Disease Primers.
Ranks and citation indicators: 2024. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2021–2023, the window the 2024 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Fields in Health Sciences (5)
Up to All journals5,549 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2023. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2021–2023, the window the 2024 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2021–2023 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2015 to 2024. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 171.61Q1 | 276.75 417.78 down from 2023 | 83 | 100% | $4,330 | ||
2MMWR Surveillance SummariesOACenters for Disease Control and Prevention · United States | 29.38Q1 | 71.42 16.04 up from 2023 | 30 | 100% | — | ||
3Nature Reviews Disease PrimersNature Portfolio · United Kingdom | 13.63Q1 | 54.45 15.91 down from 2023 | 137 | 25% | — | ||
4The LancetElsevier BV · Netherlands | 11.89Q1 | 26.10 6.67 down from 2023 | 2,556 | 33% | $7,890 | ||
5New England Journal of MedicineMassachusetts Medical Society · United States | 11.78Q1 | 32.11 1.40 down from 2023 | 2,787 | 22% | — | ||
6Nature MedicineNature Portfolio · United States | 11.10Q1 | 32.79 8.24 down from 2023 | 1,239 | 55% | $12,690 | ||
7Endocrine ReviewsOxford University Press · United States | 10.56Q1 | 26.42 0.93 up from 2023 | 110 | 85% | $3,750 | ||
8Periodontology 2000Wiley · United Kingdom | 8.49Q1 | 18.19 1.88 down from 2023 | 166 | 84% | $4,430 | ||
9Journal of Hematology & OncologyOABioMed Central · United Kingdom | 8.20Q1 | 30.21 5.83 up from 2023 | 467 | 100% | $4,990 | ||
10Clinical Microbiology ReviewsAmerican Society for Microbiology · United States | 8.20Q1 | 22.69 0.78 up from 2023 | 88 | 100% | — | ||
11The Lancet NeurologyElsevier BV · Netherlands | 7.88Q1 | 18.10 1.18 down from 2023 | 578 | 32% | $7,280 | ||
12CirculationLippincott Williams & Wilkins · United States | 7.85Q1 | 22.79 2.47 up from 2023 | 1,425 | 6% | — | ||
13Nature Reviews Clinical OncologyNature Portfolio · United Kingdom | 7.54Q1 | 32.27 0.65 down from 2023 | 367 | 13% | — | ||
14The Lancet Diabetes & EndocrinologyElsevier BV · Netherlands | 7.50Q1 | 18.22 1.68 down from 2023 | 442 | 36% | $7,280 | ||
15Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 7.33Q1 | 20.22 0.05 down from 2023 | 1,474 | 47% | — | ||
16Cancer CellCell Press · Netherlands | 7.21Q1 | 27.49 5.82 up from 2023 | 544 | 99% | $10,400 | ||
17The Lancet OncologyElsevier BV · United Kingdom | 6.99Q1 | 17.76 3.32 down from 2023 | 907 | 30% | $7,280 | ||
18Cancer DiscoveryAmerican Association for Cancer Research · United States | 6.85Q1 | 23.50 1.10 down from 2023 | 560 | 32% | — | ||
19MMWR Morbidity and Mortality Weekly ReportOACenters for Disease Control and Prevention · United States | 6.21Q1 | 18.23 5.88 down from 2023 | 815 | 100% | — | ||
20Journal of HepatologyElsevier BV · Denmark | 5.99Q1 | 16.60 0.47 up from 2023 | 1,163 | 16% | $5,500 | ||
21European Heart JournalOxford University Press · United Kingdom | 5.80Q1 | 13.82 2.69 down from 2023 | 1,955 | 53% | $5,922 | ||
22The Lancet Digital HealthOAElsevier BV · United Kingdom | 5.74Q1 | 20.05 0.63 up from 2023 | 343 | 100% | $6,680 | ||
23Progress in Retinal and Eye ResearchElsevier BV · Netherlands | 5.71Q1 | 15.01 0.14 down from 2023 | 132 | 83% | $6,710 | ||
24The Lancet. Gastroenterology & hepatologyElsevier BV · United Kingdom | 5.45Q1 | 17.45 2.88 up from 2023 | 543 | 28% | $7,280 | ||
25Journal of the American College of CardiologyElsevier BV · United States | 5.35Q1 | 14.34 1.13 up from 2023 | 1,622 | 99% | $7,166 | ||
26DrugsAdis, Springer Healthcare · New Zealand | 5.24Q1 | 15.66 1.06 up from 2023 | 432 | 60% | $5,990 | ||
27Current Obesity ReportsSpringer Science+Business Media · United States | 5.17Q1 | 13.43 1.30 up from 2023 | 110 | 56% | $5,790 | ||
28Implementation ScienceOABioMed Central · United Kingdom | 5.15Q1 | 14.65 2.79 up from 2023 | 245 | 100% | $3,390 | ||
29GutBMJ · United Kingdom | 5.03Q1 | 15.68 0.47 up from 2023 | 835 | 53% | — | ||
30Nature CancerNature Portfolio · United States | 5.02Q1 | 18.86 2.89 up from 2023 | 440 | 47% | $12,690 | ||
31Molecular NeurodegenerationOABioMed Central · United Kingdom | 4.99Q1 | 16.40 1.50 up from 2023 | 245 | 100% | $3,090 | ||
32Diabetes CareAmerican Diabetes Association · United States | 4.94Q1 | 13.99 1.05 up from 2023 | 1,330 | 84% | — | ||
33The Lancet Respiratory MedicineElsevier BV · Netherlands | 4.83Q1 | 14.04 3.74 down from 2023 | 622 | 36% | $7,280 | ||
34Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 4.78Q1 | 14.18 0.64 up from 2023 | 572 | 24% | — | ||
35JAMA NeurologyAmerican Medical Association · United States | 4.74Q1 | 11.84 1.04 up from 2023 | 688 | 57% | — | ||
36npj Digital MedicineOANature Portfolio · United States | 4.69Q1 | 18.52 1.93 up from 2023 | 585 | 100% | $4,090 | ||
37AutophagyTaylor & Francis · United States | 4.65Q1 | 12.62 1.52 up from 2023 | 562 | 99% | — | ||
38Nature Reviews Gastroenterology & HepatologyNature Portfolio · United Kingdom | 4.55Q1 | 18.66 0.46 up from 2023 | 454 | 19% | — | ||
39HepatologyLippincott Williams & Wilkins · United States | 4.48Q1 | 14.77 3.59 up from 2023 | 1,054 | 36% | $2,900 | ||
40Medical Image AnalysisElsevier BV · United Kingdom | 4.47Q1 | 15.82 3.46 up from 2023 | 870 | 59% | $4,170 | ||
41NEJM EvidenceUnited States | 4.42Q1 | 11.19 0.32 down from 2023 | 294 | 23% | — | ||
42European UrologyElsevier BV · Switzerland | 4.40Q1 | 13.40 2.98 up from 2023 | 650 | 14% | $5,250 | ||
43Translational NeurodegenerationOABioMed Central · China | 4.27Q1 | 16.39 4.82 up from 2023 | 158 | 100% | $2,990 | ||
44The Lancet Infectious DiseasesElsevier BV · Netherlands | 4.26Q1 | 12.65 3.52 down from 2023 | 1,031 | 35% | $7,280 | ||
45Human Reproduction UpdateOxford University Press · United Kingdom | 4.26Q1 | 18.16 3.51 up from 2023 | 115 | 75% | $4,490 | ||
46Nature Reviews CardiologyNature Portfolio · United Kingdom | 4.20Q1 | 15.67 0.61 down from 2023 | 468 | 26% | — | ||
47Neuro-OncologyOxford University Press · United States | 4.16Q1 | 9.86 3.66 down from 2023 | 718 | 100% | $5,132 | ||
48PLoS MedicineOAPublic Library of Science · United States | 4.15Q1 | 10.42 2.35 down from 2023 | 702 | 100% | $6,460 | ||
49Endocrine PathologySpringer Science+Business Media · United States | 4.14Q1 | 14.80 1.50 up from 2023 | 127 | 51% | $3,190 | ||
50BMJ MedicineOABMJ · United Kingdom | 4.05Q1 | 10.41 3.77 up from 2023 | 104 | 100% | $3,679 |
Fields of Health Sciences, compared.
Journals
Citations made in 2024. Corpus-wide, 87.1% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
1,140 additional Health Sciences journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2021–2023, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2024. Publication window: 2021–2023. How these summaries are calculated
- Ranked journals
- 5,549
- Window papers (baseline)
- 3,507,496 +13.9% from indicator year 2021
- Median OJR
- 0.681 +0.1% from indicator year 2021
- Rising journals (2025)
- 464
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2021–2023 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 2,007 | 2,150 | 2,285 | 2,374 | 2,486 | 2,626 | 2,757 | 2,922 | 3,062 | 3,193 | 3,364 | 3,591 | 3,809 | 4,129 | 4,361 | 4,544 | 4,757 | 4,979 | 5,239 | 5,390 | 5,462 | 5,563 | 5,606 | 5,618 | 5,549 | 5,406 | |
| Window papers (baseline) | 813,419 | 909,304 | 974,228 | 1,051,248 | 1,094,845 | 1,200,886 | 1,317,521 | 1,455,690 | 1,577,275 | 1,733,757 | 1,887,930 | 2,035,231 | 2,126,669 | 2,204,628 | 2,320,572 | 2,437,477 | 2,534,543 | 2,585,157 | 2,649,222 | 2,728,712 | 2,846,138 | 3,078,764 | 3,332,730 | 3,490,788 | 3,507,496 | 3,550,948 | |
| Median OJR | 0.50 | 0.53 | 0.56 | 0.59 | 0.61 | 0.63 | 0.6778 | 0.70 | 0.726 | 0.748 | 0.767 | 0.773 | 0.78 | 0.741 | 0.76 | 0.750 | 0.737 | 0.727 | 0.71 | 0.725 | 0.735 | 0.680 | 0.67 | 0.6776 | 0.681 | 0.69 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 3.3% | 4,151 journals |
| Retracted papers per 1,000 | Pooled rate: 1.372 per 1,000 | 4,101 journals |
| Output growth | Median: -6.3% | 5,009 journals |
| Open access share | Median: 100.0% | 5,406 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,090 | 2,959 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 20.2% | 5,241 journals |
| Review share | Median: 2.7% | 5,406 journals |
| Articles-only OJR | Median: 0.70 | 5,372 journals |
| Uncited share | Median: 37.7% | 5,406 journals |
| Citation concentration | Median: 46.2% | 5,398 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.